LOGIN  |  REGISTER
Recursion
C4 Therapeutics

Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

December 02, 2024 | Last Trade: US$4.40 0.34 -7.17

GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present body composition data from the Phase 2 MOMENTUM trial of pemvidutide in the treatment of obesity and participate in a panel discussion at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders in Washington, D.C.  

Details for the panel discussion are as follows:

Title:Muscle Wasting in Weight Loss Therapy
Session:Treatment Approaches to Address Muscle Wasting in the Context of Obesity Therapy & Regulatory Issues
Presenter:Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc.
Date/Time:Friday, December 6, 2024 at 9:30 am ET

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.  For more information, please visit www.altimmune.com

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
This email address is being protected from spambots. You need JavaScript enabled to view it.

This press release was published by a CLEAR® Verified individual.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page